A 52-Week Study of Ritlecitinib Oral Capsules in Adults and Adolescents with Vitiligo (Active and Stable)
2 Primary · 11 Secondary · Reporting Duration: 36 and 52 weeks
Experimental Treatment
Non-Treatment Group
600 Total Participants · 2 Treatment Groups
Primary Treatment: Ritlecitinib 50 mg · Has Placebo Group · Phase 3
Age Any Age · All Participants · 10 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you: